All Updates

All Updates

icon
Filter
M&A
Lantern Pharma forms new subsidiary, Starlight Therapeutics, to focus on CNS and brain cancer treatments
AI Drug Discovery
Mar 6, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 6, 2023

Lantern Pharma forms new subsidiary, Starlight Therapeutics, to focus on CNS and brain cancer treatments

M&A

  • Texas-based AI biopharmaceutical company Lantern Pharma has launched a new wholly-owned subsidiary called “Starlight Therapeutics,” dedicated to developing novel treatments focused on the central nervous system (CNS) and brain cancers. 

  • Following the launch of Starlight, Lantern’s small molecule candidate, LP-184, will be referred to as STAR-001 for CNS indications while Lantern will continue to evaluate and advance LP-184 for other non-CNS indications. 

  • The formation of Starlight is expected to increase the probability of securing partnerships with other biotech and biopharma companies that focus on CNS cancers. Starlight will also be able to leverage Lantern’s AI-powered platform, RADR, to accelerate the discovery of novel therapeutics. 

  • Lantern expects to initiate Phase Ia clinical trials of STAR-001 for a number of cancer indications, including glioblastoma (GBM), brain metastases, and several rare pediatric CNS cancers from mid-2023. Following this, Starlight will be solely responsible for conducting further clinical trials for STAR-001.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.